Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Kiniksa Pharmaceuticals International, plc reported revenue of $678M, up 60.1% year over year. Operating margin was 11.4% and net margin 8.7%, on a free-cash-flow margin of 20.1% with capital expenditure at 0.2% of revenue. Every figure is computed directly from KNSA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $678M | 11.4% | 8.7% |
| FY2024 | $423M | -10.8% | -10.2% |
| FY2023 | $270M | -9.3% | 5.2% |
| FY2022 | $220M | 4.4% | 83.3% |
| FY2021 | $39M | -406.4% | -409.7% |
How does KNSA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.